Vertex Pharmaceuticals Incorporated (VRTX) PT Nudged Higher as RBC Updates Biotech Sector Outlook
TheFly reported on April 7 that RBC Capital Markets slightly increased its price target on VRTX from $541 to $543 while maintaining an Outperform rating.









